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Human cancer risk assessment at a genetic level involves the investigation ofcarcinogen metabolism and
DNA adduct formation. Wide interindividual differences in metabolism resultin different DNA adduct levels.
Forthisand otherreasons, manylaboratorieshaveconsideredDNAadductstobe ameasureofthebiologically
effective dose of a carcinogen. Techniques for-studying DNA gdducts using chemically specific assays are
becoming available. A.modification of the 32P-postlabeling assay for polycyclic aromatic hydrocarbon DNA
adducts described here provides potential improvements in-quantification. DNA adducts, however, reflect only
recent exposure to carcinogens; in contrast, genetic testing for metabolic capacity indicates the extent to
which carcinogens can be activated and exert genotoxic effects. Such studies may reflect both separate and
integrated risk factors together with DNA adduct levels. A recently described restriction fragment length
polymorphism for the CYPIA1, which codes for the cytochrome P450 enzyme primarily responsible for the
metabolic activation ofcarcinogenic polycyclic aromatic hydrocarbons, has been found to be associated with
lungcancerriskin aJapanese population. Inasubsetofindividualsenrolledin aU.S.lungcancercase-control
study, no association with lung cancer was found.
Introduction
Carcinogenesis is a multistage process involving initia-
tion, promotion, conversion, and progression. Carcinogens
can influence these stages through the formation ofDNA
adducts. The level of carcinogen DNA adducts is the end
result of exogenous exposure, internal absorption, meta-
bolic activation, detoxication, and DNA repair; however,
substantial interindividual variations in these activities
have been observed. Techniques for studying both car-
cinogen metabolism (phenotyping and genotyping) and
carcinogen exposure (carcinogen-macromolecular adducts)
are nowbecoming available. These can be viewed as sepa-
rate or integrated cancer risk factors. Measurement of
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carcinogen-DNA adducts (or a surrogate) reflects recent
exposure(daystomonths),whilemetabolicphenotyping or
genotypingreflects acapabilitypossessed throughoutthe
lifetime ofan individual.
Polycyclic aromatic hydrocarbons (PAHs), metabolized
by cytochrome P4501A1 (CYPlAl) and other cytochrome
P450s, are ubiquitous in the environment and can cause
cancer in laboratory animals. Adducts can be pro-
mutagenic, display site specificity, and activate proto-
oncogenes (1-3).Adductlevels canbemeasured inhumans
by enzyme immunoassays and have been found to be
correlated with exposure to coke-oven emissions, foundry
work, tobacco, and diet (4-6) although not consistently.
Putative adducts have also been measured by the 32p_
postlabelingassay(7), andlevelshavebeencorrelatedwith
tobacco consumption (8,9); however, the lack of chemical
specificity of the current assay limits its ability to deter-
mine the actual level and adduct type.
CYPlAl is partly responsible for the metabolic activa-
tion of PAHs. It is inducible by exposure to these com-
pounds and other agents, e.g., 2,3,7,8-tetrachlorodibenzo-
p-dioxin. No direct measure ofthe capacity ofhumans to
metabolize PAHs hasbeen developed, althoughtheresults
ofcellandtissue culture studiesindicatethatwideinterin-SHIELDS ET AL.
dividual variation exists. Moreover, higher levels of aryl
hydrocarbonhydroxylase activityandPAH adductforma-
tion have been reported in lymphocytes ofcancerpatients
compared to controls (10,11). Levels ofwild-type CYPlAl
mRNA have been measured in normal lung tissue, but no
correlation with lung cancer risk was found although an
abnormal mRNA species was identified in tumor tissues
(12). Significantly higher levels were found in tobacco
smokers, confirming the inducibility by this agent. A
recentreportbyKawajirietal. (13)statedthatanMspIre-
striction fragment length polymorphism (RFLP) was
positively correlated with lung cancer risk in a Japanese
population. Individuals homozygous for the MspI
restriction site-present allele had an odds ratio for cancer
of 3.1 when compared to individuals homozygous for the
site-absentallele(predominantallele).Theassociationwas
strongest in people with squamous-cell carcin6ma of the
lung. An important limitation ofthis study, however, was
use ofdata for historical control subjects;'specifically, the
studywas notcontrolled foreither age ortobacco use. We
have now performed a pilot epidemiologic study of 78
individuals, controlling for age, race, and smoking.
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Methods
Analysis ofCYPlA1 Polymorphism
DNA samples from 78 individuals enrolled in a case-
control study of lung cancer were analyzed using the
polymerase chain reaction (PCR) and MspI restriction
digest. Primers flanking a polymorphic MspI restriction
site were used to amplify a 348-bp fragment of genomic
DNA(13). Products ofPCR were then digested to comple-
tion with MspI and analyzed on agarose gels (1.8%).
32p-postlabeling Assay
Benzo[a]pyrene-DNA adduct standards were synthe-
sized by modifying calf thymus DNA with r-7,t-8-di-
hydroxy-t-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene
(benzo[a]pyrene diol epoxide). Modified DNA was enzy-
matically digested to 3'-monophosphate-nucleotides and
purified by reverse-phase high-performance liquid chro-
matography. Adduct levels were quantified on the basis of
ultraviolet extinction coefficients and fluorescence spec-
t Cut
FIGURE 1. Chromatographic separation (A) allows for localization and quantification ofunmodified 2'-deoxyguanosine-3'-monophosphate (dGp) and
benzo[a]pyrene-diol epoxide(BPDE)-dGp.AfterdevelopmentinDl (1.25LiCI),theplatesarewashedinmethanolandthencutinhalfwithscissors.Each
plateis then developed separately. Theleft-hand sidewith theunmodified nucleotide, isdeveloped in2A(saturated ammoniumsulfate/isopropanol/1 M
sodium acetate: 80/2/18v/v) while the right-hand side is developed in D2B (2.3 M sodium phosphate, pH 6), D3 (3.5 M lithium formate/8.5 M urea, pH
3.5), and D4 (1.2 M lithium chloride/0.5 MTris-HCV8.5 Murea,pH 8.0). Atypical autoradiograph is shown inwhich therightand lefthalves havebeen
rejoined for demonstration purposes. The cutting area is shown.
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troscopy. The adducts were then mixed, in known quan-
tities, with 70 pmole of 2'-deoxyguanosine-3'-monophos-
phate (dGp) (internal standard) and postlabeled as
previously reported (14) exceptthatkinase treatmentwas
for 30 min. The samples were then applied to polyethyl-
eneimine cellulose thin-layer chromatography plates
(Machery Nagel, Germany; 20 x 20 cm) and developed in
multipledimensions, asdescribed (Fig.1).UnmodifieddGp
and adducts were localized by autoradiography and
scraped, and the radioactivity was measured by liquid
scintillation counting. Directmolarratios ofadductlevelto
dGp were then determined on the basis of counts per
minute.
Results and Discussion
The recently described MspI polymorphism, which cor-
relates with lung cancer risk in Japanese individuals, was
tested in randomindividuals and in 78 U.S. study subjects
accrued in a formal case-control study of lung cancer. A
comparison was made between Southern blot analysis
using CYPlAl cDNA (kindly provided by F. J. Gonzalez,
National Cancer Institute, Bethesda, MD) and PCR anal-
ysis (Fig. 2). There was 100% agreement between the two
methods, except for one individual who had a single band
at 1.3 kb (ratherthan 2.3 and/or 1.9 kb). The PCR analysis
showed that this person had a homozygote site-absent
genotype indicating deletion of a segment 5' to the MspI
polymorphic site. Further analysis of this individual is
warranted.
*The genotype distributions in the case-control study
(homozygote site-absent, heterozygotes, and homozygote
site-present) were not significantly different in cases and
controls. A trend indicating more site-present alleles in
people with squamous-cell carcinoma than in those with
otherhistological typeswas found, butthiswas notstatis-
tically significant. These data suggest that in a U.S. popu-
lation, the MspI polymorphism of CYPlAl is not assoc-
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FIGURE 3. Calibration curve showing directly determined molar ratios
for benzo[a]pyrene-diol epoxide-2'-deoxyguanosine-3'-monophosphate
2'-deoxyguanosine versus the known ratio.
iated with an increased risk for lung cancer. We are
currently expanding this study by analyzing additional
samples to generate sufficient power to detect a shift in
allelic frequencies in racial subgroups.
The biological relationship of the MspI polymorphism,
which is located approximately 1.5 kb to the 3' end ofthe
CYP1Al structural gene, remains undetermined. Studies
are underway to determine ifthere is an association with
aryl hydrocarbon hydroxylase induction and activity or
with CYPlAJ mRNA levels. Should an association ofthis
polymorphism with biological function exist in vivo, then
an association with PAH-DNA adduct levels can also be
sought.
Determination of carcinogen adduct levels by the 32p-
postlabeling assay is useful for testing the biological sig-
nificance of interindividual variation in metabolism; such
adducts are probably also an important independent risk
factor for cancer. This assay has been widely used for the
detection of adducts in single and multiple biological sys-
tems; however, inherentlimitations resultfrom difficulties
in determining specific PAH adductlevels.
We areattemptingtodevelopachemicallyspeciflc assay
to complement the use of the 32P-postlabeling assay in
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FIGURE 2. DNA samples were amplified bypolymerase chain reaction and then digested with MspI. A reverse image ofan agarose gel (1.8%) shows
homozygous site-absent (lanes C, D, F, H, I, J), heterozygous (lanes A, B, E) and homozygous site-present (lanes G, K, L) allelotypes.
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screening. A similar strategy to thatused for detection of
alkyl adducts has been employed (15). To this end, we are
modifying the 32P-postlabeling assay to include the use of
an internal standard (dGp); incorporating high perfor-
mance liquid chromatography for adduct purification and
assessing enzymatic digestion; and developing calibration
curves using authentically synthesized DNA adducts and
determining molar ratios, rather than relying on determi-
nations of relative adduct labeling that assume complete
labeling efficiency. A representative autoradiogram for
7R,8S,9S-trihydroxy-1OR-(N2-deoxyguanosyl-3'-phos-
phate)-7,8,9,10-tetrahydrobenzo[a]pyrene isshowninFig-
ure 1. The labelingefficiency was found tovary slightlyby
adduct concentration (Fig. 3), consistentwith the findings
of other authors (16,17). The resulting limit of detection
was 7.0 fmole ofadduct.
This manuscript was presented as a poster at the Conference on
Biomonitoring and Susceptibility Markers in Human Cancer: Applica-
tions in Molecular Epidemiology and Risk Assessment that was held in
Kailua-Kona, Hawaii, 26 October-1 November 1991.
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